MX371053B - Anticuerpos anti-ige humanizados que reticulan cd23 en los linfocitos b pero no sensibilizan los mastocitos. - Google Patents
Anticuerpos anti-ige humanizados que reticulan cd23 en los linfocitos b pero no sensibilizan los mastocitos.Info
- Publication number
- MX371053B MX371053B MX2016015838A MX2016015838A MX371053B MX 371053 B MX371053 B MX 371053B MX 2016015838 A MX2016015838 A MX 2016015838A MX 2016015838 A MX2016015838 A MX 2016015838A MX 371053 B MX371053 B MX 371053B
- Authority
- MX
- Mexico
- Prior art keywords
- ige
- lymphocytes
- mast cells
- bound
- humanized anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se divulga un novedoso anticuerpo anti-IgE humanizado. El anticuerpo es capaz de enlazarse a IgE libre, IgE enlazado a membrana en linfocitos B, IgE enlazado por CD23, pero no a IgE enlazado por un receptor IgE.Fc de alta afinidad en los mastocitos. La presente invención se relaciona con el tratamiento de enfermedades mediadas por IgE, incluyendo asma alérgica, rinitis alérgica, dermatitis atópica, alergia alimentaria, urticaria (idiopática) espontánea crónica, rinosinusitis crónica, mastocitosis sistémica, mastocitosis cutánea, aspergilosis broncopulmonar alérgica, angioedema idiopática recurrente y trastorno gastrointestinal asociado con eosinófilos administrando el anticuerpo anti-IgE de la presente invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462013196P | 2014-06-17 | 2014-06-17 | |
PCT/US2015/035981 WO2015195631A1 (en) | 2014-06-17 | 2015-06-16 | HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016015838A MX2016015838A (es) | 2017-02-02 |
MX371053B true MX371053B (es) | 2020-01-14 |
Family
ID=54936031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016015838A MX371053B (es) | 2014-06-17 | 2015-06-16 | Anticuerpos anti-ige humanizados que reticulan cd23 en los linfocitos b pero no sensibilizan los mastocitos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US10047166B2 (es) |
EP (1) | EP3157951B1 (es) |
JP (1) | JP6397938B2 (es) |
KR (1) | KR101892837B1 (es) |
CN (1) | CN106573972B (es) |
AU (1) | AU2015277379B2 (es) |
CA (1) | CA2943588C (es) |
DK (1) | DK3157951T3 (es) |
ES (1) | ES2811303T3 (es) |
MX (1) | MX371053B (es) |
NZ (1) | NZ723520A (es) |
PT (1) | PT3157951T (es) |
SG (1) | SG11201607046VA (es) |
TW (1) | TWI542598B (es) |
WO (1) | WO2015195631A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3565587A4 (en) * | 2017-01-06 | 2020-12-16 | The Regents of The University of California | THERAPEUTIC ANTI-IGE ANTIBODIES AND RELATED METHODS AND COMPOSITIONS |
EP3882274A4 (en) * | 2018-09-21 | 2022-06-29 | Riken | Anti-ige antibody specifically binding to membrane-bound ige antibody of ige antibody-producing b cells and method for diagnosing and treating allergic symptoms using the same |
CN113372450A (zh) * | 2020-03-10 | 2021-09-10 | 北京万华生物工程有限公司 | IgE嵌合性双特异性抗体制备及应用 |
RU2760825C1 (ru) * | 2020-11-30 | 2021-11-30 | Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской Федерации | Способ лечения больных аллергическим ринитом в сочетании с хроническим риносинуситом бактериальной этиологии с использованием отечественного топического иммунокорректора |
CN112552403A (zh) * | 2020-12-25 | 2021-03-26 | 南京英瀚斯生物科技有限公司 | 一种人源抗人CD23抗体的Fab片段、药物组合物及其应用 |
CN112646036B (zh) * | 2021-01-21 | 2022-05-31 | 苏州百道医疗科技有限公司 | 一种抗cd23特异性单克隆抗体及其应用 |
TW202332691A (zh) * | 2021-10-12 | 2023-08-16 | 聯合生物製藥股份有限公司 | Ige調節的疾病的治療 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2012217A (en) * | 1932-06-07 | 1935-08-20 | Borson Ben | Automatic bucket tally |
US4940782A (en) | 1987-06-08 | 1990-07-10 | G. D. Searle & Co. | Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore |
US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6699472B2 (en) * | 1991-08-14 | 2004-03-02 | Genentech, Inc. | Method of treating allergic disorders |
US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
DK1034298T3 (da) * | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
US20020076404A1 (en) * | 1998-01-29 | 2002-06-20 | Chang Tse Wen | Treating atopic dermatitis with IgE antagonists |
AU784187B2 (en) * | 1999-09-30 | 2006-02-16 | Kyowa Hakko Kogyo Co. Ltd. | Human type complementarity determining region transplantation antibody against ganglioside GD3 and derivatives of antibody against ganglioside GD3 |
AU2002351896A1 (en) * | 2001-12-11 | 2003-06-23 | Ablynx N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
EP1592777A4 (en) * | 2003-02-01 | 2008-06-04 | Tanox Inc | METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES |
EP1720908A2 (en) * | 2004-02-17 | 2006-11-15 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
PL2343380T3 (pl) * | 2004-11-16 | 2020-03-31 | Humanigen, Inc. | Wymiana kasety dla regionu zmiennego immunoglobuliny |
US8080249B2 (en) * | 2005-06-30 | 2011-12-20 | Risk Glifford G | Methods to treating chronic obstructive pulmonary disease |
PL2132230T3 (pl) * | 2007-03-22 | 2014-09-30 | Genentech Inc | Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną |
SG174161A1 (en) * | 2009-02-25 | 2011-11-28 | Tsewen Chang | ANTI-CemX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES |
WO2011146514A2 (en) * | 2010-05-17 | 2011-11-24 | The Board Of Regents Of The University Of Texas System | Rapid isolation of monoclonal antibodies from animals |
US9587034B2 (en) * | 2012-04-20 | 2017-03-07 | Academia Sinica | Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains |
-
2015
- 2015-06-16 CA CA2943588A patent/CA2943588C/en active Active
- 2015-06-16 WO PCT/US2015/035981 patent/WO2015195631A1/en active Application Filing
- 2015-06-16 TW TW104119331A patent/TWI542598B/zh active
- 2015-06-16 DK DK15810347.3T patent/DK3157951T3/da active
- 2015-06-16 CN CN201580031892.4A patent/CN106573972B/zh active Active
- 2015-06-16 JP JP2016571309A patent/JP6397938B2/ja active Active
- 2015-06-16 ES ES15810347T patent/ES2811303T3/es active Active
- 2015-06-16 AU AU2015277379A patent/AU2015277379B2/en active Active
- 2015-06-16 SG SG11201607046VA patent/SG11201607046VA/en unknown
- 2015-06-16 US US15/318,360 patent/US10047166B2/en active Active
- 2015-06-16 PT PT158103473T patent/PT3157951T/pt unknown
- 2015-06-16 NZ NZ723520A patent/NZ723520A/en unknown
- 2015-06-16 MX MX2016015838A patent/MX371053B/es active IP Right Grant
- 2015-06-16 EP EP15810347.3A patent/EP3157951B1/en active Active
- 2015-06-16 KR KR1020167028831A patent/KR101892837B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CN106573972B (zh) | 2021-04-06 |
US10047166B2 (en) | 2018-08-14 |
AU2015277379B2 (en) | 2017-06-29 |
AU2015277379A1 (en) | 2016-09-08 |
MX2016015838A (es) | 2017-02-02 |
EP3157951B1 (en) | 2020-05-13 |
CA2943588A1 (en) | 2015-12-23 |
CA2943588C (en) | 2019-04-30 |
TWI542598B (zh) | 2016-07-21 |
TW201600528A (zh) | 2016-01-01 |
PT3157951T (pt) | 2020-08-24 |
EP3157951A4 (en) | 2017-12-13 |
DK3157951T3 (da) | 2020-08-17 |
WO2015195631A1 (en) | 2015-12-23 |
EP3157951A1 (en) | 2017-04-26 |
NZ723520A (en) | 2018-06-29 |
JP2017518320A (ja) | 2017-07-06 |
ES2811303T3 (es) | 2021-03-11 |
KR20160131115A (ko) | 2016-11-15 |
SG11201607046VA (en) | 2016-10-28 |
KR101892837B1 (ko) | 2018-08-28 |
US20170121425A1 (en) | 2017-05-04 |
CN106573972A (zh) | 2017-04-19 |
JP6397938B2 (ja) | 2018-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016015838A (es) | Anticuerpos anti-ige humanizados que reticulan cd23 en los linfocitos b pero no sensibilizan los mastocitos. | |
MX2023004306A (es) | Un antagonista de il-4r para usarse en prevenir o tratar la alergia. | |
ZA201703121B (en) | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists | |
MX2022011659A (es) | Proteinas de union a antigeno que se unen a pd-l1. | |
WO2015184001A8 (en) | Anti-tnf-alpha glycoantibodies and uses thereof | |
GEP20227419B (en) | Pd-1-binding molecules and methods of use thereof | |
WO2014194302A3 (en) | Antigen binding proteins that bind pd-1 | |
PH12016500943A1 (en) | Aplnr modulatros and uses thereof | |
EA202192165A1 (ru) | Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы | |
WO2014189973A3 (en) | Anti-transferrin receptor antibodies and methods of use | |
EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
EA202091315A2 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
EP4286011A3 (en) | Fcrn antibodies and methods of use thereof | |
PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
EP4219552A3 (en) | Il-11r binding proteins and uses thereof | |
WO2013181634A3 (en) | Antigen binding proteins that bind pd-l1 | |
WO2015031815A3 (en) | Antibodies and assays for detection of folate receptor 1 | |
WO2014184545A3 (en) | Engineered fc variants | |
WO2013188448A8 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
MX2020003503A (es) | Proteinas de union al antigeno del receptor de oncostatina m. | |
WO2015187992A3 (en) | Map44 polypeptides and constructs based on natural antibodies and uses thereof | |
PH12019500342A1 (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
WO2016011035A8 (en) | Neutralizing anti-influenza b antibodies and uses thereof | |
PH12017500332A1 (en) | Antigen binding proteins that bind cxcr3 | |
EA201891594A1 (ru) | Антитела к il-17c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |